Revision 1

Store at -20C

#45084

PRAME Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	50	Rabbit	#P78395	23532

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:200

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

PRAME Antibody recognizes endogenous levels of total PRAME protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala167 of human PRAME protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

PRAME (preferentially expressed antigen in melanoma) is a cancer/testis antigen not normally expressed in any tissues except testis, but is upregulated in tumors. PRAME is expressed in melanoma cells and is recognized by cytolytic T-cells (4). It is also upregulated in other diseases, such as synovial sarcoma (5), NSCLC (6), and breast cancer, where it is thought to contribute to tumorigenesis and metastasis (7). PRAME is also highly expressed in liquid tumors such as AML (8) and can be predictive of clinical outcome in some circumstances (9). PRAME and other cancer/testis antigens are currently being pursued as novel immunotherapy targets and diagnostic biomarkers (10).

Background References

1. Caballero, O.L. and Chen, Y.T. (2009) *Cancer Sci* 100, 2014-21.
2. De Smet, C. et al. (1999) *Mol Cell Biol* 19, 7327-35.
3. Gjerstorff, M.F. et al. (2015) *Oncotarget* 6, 15772-87.
4. Ikeda, H. et al. (1997) *Immunity* 6, 199-208.
5. Iura, K. et al. (2017) *Hum Pathol* 61, 130-139.
6. Gunn, R.B. and Fröhlich, O. (1989) *Methods Enzymol* 173, 54-80.
7. Sun, Z. et al. (2016) *Gene* 594, 160-164.
8. Qin, Y.Z. et al. (2017) *Oncol Lett* 13, 2823-2830.
9. Oehler, V.G. et al. (2009) *Blood* 114, 3299-308.
10. Salmaninejad, A. et al. (2016) *Immunol Invest* 45, 619-40.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.